Cohance Lifesciences Limited (COHANCE) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Cohance Lifesciences Limited stock ₹158, price ₹459, that is 65.6% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Cohance Lifesciences Limited
COHANCE · NSEFar too expensive (fair value 66% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range ₹279.90 – ₹1,334 · fair‑value band ₹87.29 – ₹197.09 · the ₹458.60 price screens above the ₹157.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Every Wednesday you see whether Cohance Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.
Show moreShow less
The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals.
It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India.
Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Stock analysis
Cohance Lifesciences Limited (COHANCE) currently trades at ₹458.60, while our model-based Fair Value estimate is ₹157.67, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹131.59 per share, and 0 of the 24 models we run sit above the ₹458.60 price.
Bear case: the Asset-Based group reads lowest at ₹44.27, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹87.29 (bear) to ₹197.09 (bull), the price of ₹458.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Cohance Lifesciences Limited reported revenue of ₹22.7B in FY2026 versus ₹13.2B in FY2022, a compound +14.5%/yr. Reported net income was ₹1.8B in FY2026, compounding −20.7%/yr from FY2022.
Key figures
Market cap ₹176B (≈ $1.9B) Small · P/E ratio 385.4 · P/S ratio 30.4 · EPS (TTM) ₹1.19 · Net margin 7.9% · Return on equity 3.8% · Return on assets (EBIT) 22.7% (5-year average) · Operating margin −11.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 27% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −66%, COHANCE screens richer than that median.
Fair Value models
All 24 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
COHANCE screens overvalued: fair value 66% below the price. Compare with Merck KGaA →
Compare Cohance Lifesciences Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs COHANCE |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs COHANCE |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs COHANCE |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs COHANCE |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs COHANCE |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs COHANCE |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs COHANCE |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs COHANCE |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs COHANCE |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs COHANCE |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cohance Lifesciences Limited (COHANCE) overvalued or undervalued?
What is the fair value of COHANCE?
What is the quality score of COHANCE?
What is the price target for Cohance Lifesciences Limited (COHANCE)?
What is the Cohance Lifesciences Limited stock forecast for 2026?
What is the revenue of Cohance Lifesciences Limited (COHANCE)?
What growth is priced into Cohance Lifesciences Limited (COHANCE)?
What discount rate (WACC) does the fair value of COHANCE use?
What is a reverse DCF?
How much growth has Cohance Lifesciences Limited (COHANCE) delivered so far?
How fast is the sector of Cohance Lifesciences Limited (COHANCE) growing?
What is the free cash flow yield of Cohance Lifesciences Limited (COHANCE)?
What is the intrinsic value of Cohance Lifesciences Limited (COHANCE)?
Is Cohance Lifesciences Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of COHANCE?
How much is Cohance Lifesciences Limited worth?
What do the bullish and bearish scenarios say about COHANCE?
What is the P/E ratio of COHANCE?
How solid is the balance sheet of Cohance Lifesciences Limited (COHANCE)?
How far is COHANCE from its 52-week high?
Which stocks are comparable to Cohance Lifesciences Limited?
Is Cohance Lifesciences Limited stock attractive at the current price?
How is the fair value of COHANCE calculated?
Is it still worth investing in stocks now?
What is the share price of Cohance Lifesciences Limited (COHANCE)?
What should I pay attention to with Cohance Lifesciences Limited right now?
Key figures of Cohance Lifesciences Limited
How large is the market capitalisation of Cohance Lifesciences Limited (COHANCE)?
What is the P/S ratio of Cohance Lifesciences Limited (COHANCE)?
What are the earnings per share of Cohance Lifesciences Limited (COHANCE)?
What is the net margin of Cohance Lifesciences Limited (COHANCE)?
What is the return on equity of Cohance Lifesciences Limited (COHANCE)?
What is the EBIT return on assets of Cohance Lifesciences Limited (COHANCE)?
What is the operating margin of Cohance Lifesciences Limited (COHANCE)?
How fast is revenue growing at Cohance Lifesciences Limited (COHANCE)?
How fast are earnings growing at Cohance Lifesciences Limited (COHANCE)?
How much net debt does Cohance Lifesciences Limited (COHANCE) carry?
Watch Cohance Lifesciences Limited in the live analysis
One click puts Cohance Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.